5 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 11 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 5, Recruiting 2, Unknown 2, Active not recruiting 1, Suspended 1 |
| Phase 1 | 7 | Completed 4, Unknown 2, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Color Vision Defects: new trials by email Literature Review of Color Vision Defects trials Research Report on Color Vision Defects
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Naturally Produced Cannabinoids for Neuroprotection From Concussion Broad spectrum cannabinoid formulation, Placebo gel capsule - Healthy | Phase 2 | Recruiting | University of Regina | 60 | 2026-06-01 | 2026-07-21 |
| Alcohol Use Disorder and Cannabidiol Cannabidiol, Placebo - Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 180 | 2023-04-30 | 2026-06-15 |
| Patient-centered Modular CBT for CPTSD: A Randomised Controlled Pilot Study Psychotherapy - Complex Post-Traumatic Stress Disorder | Phase 1 / Phase 2 | Completed | Danish Veterans Centre | 60 | 2021-01-05 | 2025-04-02 |
| Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder CBD Isolate, CBD Broad Spectrum, Placebo oil - Post Traumatic Stress Disorder | Phase 2 | Suspended | University of Texas at Austin | 150 | 2020-01-15 | 2023-11-22 |
| Gene Therapy for Achromatopsia (CNGA3) adeno-associated virus vector AAV- CNGA3 - Achromatopsia | Phase 1 / Phase 2 | Completed | MeiraGTx UK II Ltd | 11 | 2019-08-12 | 2022-12-01 |
| Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial) AGTC-402 - Achromatopsia | Phase 1 / Phase 2 | Unknown | Beacon Therapeutics | 24 | 2017-08-03 | 2022-07-22 |
| Gene Therapy for Achromatopsia (CNGB3) AAV - CNGB3 - Achromatopsia | Phase 1 / Phase 2 | Completed | MeiraGTx UK II Ltd | 23 | 2017-01-16 | 2023-03-08 |
| Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial) rAAV2tYF-PR1.7-hCNGB3 - Achromatopsia | Phase 1 / Phase 2 | Unknown | Beacon Therapeutics | 32 | 2016-04-11 | 2022-07-22 |
| Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia rAAV.hCNGA3 - Achromatopsia | Phase 1 / Phase 2 | Active not recruiting | STZ eyetrial | 13 | 2015-11-01 | 2024-04-18 |
| CNTF Implants for CNGB3 Achromatopsia NT-501 CNTF-releasing implant - Eye Disease, Achromatopsia | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2012-07-01 | 2016-11-21 |
| Booster as an Adjunct to Internet-based Cognitive Behavior Therapy (CBT) Booster - Obsessive-compulsive Disorder | Phase 2 | Completed | Karolinska Institutet | 98 | 2012-02-01 | 2012-07-31 |
Eye Diseases (2) · Marijuana Abuse (2) · Alcoholism (1) · Brain Concussion (1) · Inflammation (1) · Nervous System Diseases (1) · Neurologic Manifestations (1) · Obsessive-Compulsive Disorder (1) · Sensation Disorders (1) · Signs and Symptoms (1) · Stress Disorders, Post-Traumatic (1) · Vision Disorders (1)
Cone Dystrophy (11) · Eye Diseases, Hereditary (11) · Pathological Conditions, Signs and Symptoms (11) · Nervous System Diseases (10) · Neurologic Manifestations (10) · Sensation Disorders (10) · Signs and Symptoms (10) · Vision Disorders (10) · Eye Diseases (9) · Mental Disorders (4) · Chemically-Induced Disorders (2) · Substance-Related Disorders (2) · Alcohol-Related Disorders (1) · Anxiety Disorders (1) · Brain Diseases (1)
Cannabidiol (1) · Immunization, Secondary (1) · Psychotherapy (1)
Beacon Therapeutics (2) · MeiraGTx UK II Ltd (2) · Danish Veterans Centre (1) · Karolinska Institutet (1) · National Eye Institute (NEI) (1) · STZ eyetrial (1) · University of Colorado, Denver (1) · University of Regina (1) · University of Texas at Austin (1)
United States (7) · United Kingdom (2) · Canada (1) · Denmark (1) · Germany (1) · Israel (1) · Sweden (1)
David Jacobs, MD, MBA (2) · Dominik Fischer, Prof. (1) · James Bainbridge (1) · James Bainbridge, Prof (1) · Kent Hutchison, PhD (1) · Michael J Telch, Ph.D. (1) · Paul A Sieving, MD, PhD (1) · Sofie Folke, PhD (1)
PMID 25205868, PMID 30194931, PMID 32352493, PMID 34006508, PMID 36154908, PMID 37172884
2014 (1), 2016 (1), R01AA029606 (1), R24EY022023 (1)